A differentiated new player in the rapidly growing immuno-oncology market

Avvinity is deploying a powerful, proprietary and proven platform to discover and develop novel immuno-oncology therapeutics, called Alphamers, for both solid tumours and leukaemias.

About

Our Science

Our Leadership